Vyne Therapeutics Reports Q1 2025 Financial Results: Revenues Increase to $0.2M with Significant Rise in R&D Expenses
Vyne Therapeutics reported Q1 2025 financial results with revenues of $0.2 million, up from $0.1 million in Q1 2024. R&D expenses rose to $6.1 million, while general and administrative expenses decreased to $3.3 million. The company has $50.3 million in cash and expects to sustain operations into H2 2026. Key updates include a Phase 2b trial for vitiligo with results expected mid-2025, and a Phase 1b trial for psoriasis on clinical hold due to safety concerns, which VYNE is addressing with the FDA.
VYNE Therapeutics Inc. reported its financial results for the first quarter ending March 31, 2025. The company recorded revenues of $0.2 million, up from $0.1 million in the same period in 2024. The revenues consisted of royalty income from VYNE's agreement with LEO Pharma A/S. Research and development expenses increased to $6.1 million from $3.7 million a year earlier, driven by higher costs related to VYN202 and repibresib trials, as well as increased employee expenses. General and administrative expenses decreased to $3.3 million from $3.8 million in 2024. VYNE's cash, cash equivalents, and marketable securities totaled $50.3 million as of March 31, 2025. The company expects this cash position to sustain operations into the second half of 2026. Significant business updates include the ongoing Phase 2b trial of repibresib for treating vitiligo, with top-line results expected mid-2025. The company's Phase 1b trial of VYN202 for moderate-to-severe plaque psoriasis has been placed on clinical hold by the FDA due to testicular toxicity observed in a non-clinical study. VYNE is working with the FDA to address this issue.
